Adverse reactions : תופעות לוואי

Adverse Reactions
Clinical trial data
The safety profile presented below is based on data from clinical studies in which 530 subjects received Mencevax ACWY.
Adverse reactions occurring during these studies were mostly reported within 48 hours following vaccination.
Frequencies are reported as:
Very common: ≥ 1/10
Common:           ≥ 1/100 to < 1/10
Uncommon:         ≥ 1/1000 to < 1/100
Metabolism and nutrition disorders:
Common: appetite lost
Psychiatric disorders:
Very common: irritability
Nervous system disorders:
Very common: drowsiness, headache
Uncommon: dizziness
Gastrointestinal disorders:
Common: gastrointestinal symptoms e.g. nausea, vomiting and diarrhoea Musculoskeletal and connective tissue disorders:
Common: myalgia
General disorders and administration site conditions:
Very common: pain and redness at the injection site, fatigue
Common: swelling at the injection site, fever
Post-marketing data
In addition, the following adverse reactions have been reported during post-marketing surveillance: Immune system disorders
Allergic reactions, including anaphylactic and anaphylactoid reactions Skin and subcutaneous tissue disorders
Urticaria, rash, angioneurotic oedema
Musculoskeletal and connective tissue disorders
Arthralgia, musculoskeletal stiffness
General disorders and administration site conditions
Influenza-like symptoms, chills